As per the letter enclosed.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Eye Hospital reported FY25 revenue from operations of ₹397.15 Cr, up 24.4% from ₹319.30 Cr last year. Net profit grew to ₹54.65 Cr from ₹46.36 Cr (~18% growth), while EBITDA rose to ₹123.59 Cr from ₹96.03 Cr. Q4 FY25 revenue stood at ₹99.83 Cr with PAT of ₹15.99 Cr. The Board declared a final dividend of ₹3.50 per share, taking the total dividend for FY25 to ₹6.00 per share (60% on face value). Statutory auditor M/s Deloitte Haskins & Sells is being replaced by M/s S.R. Batliboi & Associates LLP for a 5-year term (FY26–FY30). The Board also reappointed Dr. Amar Agarwal (Chairman & MD) and Dr. Athiya Agarwal (Whole-time Director) for 3 years. Cash from operations was healthy at ₹94.48 Cr.
Strong revenue growth and consistent profitability back the higher total dividend payout, which is positive for shareholders. The auditor change is a routine end-of-term rotation, not a red flag. Overall, the results signal steady business momentum and sound cash generation.